EP4159856A1 — Novel crispr enzymes and systems
Assigned to SHMAKOV, SERGEY · Expires 2023-04-05 · 3y expired
What this patent protects
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting C2c2 CRISPR effector protein with two HEPN domains and at …
USPTO Abstract
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting C2c2 CRISPR effector protein with two HEPN domains and at least one targeting nucleic acid component like a guide RNA. The effector protein is linked to a heterologous functional domain and the HEPN domain(s) may be inactivated.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.